Status:
COMPLETED
Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Pfizer
Schering-Plough
Conditions:
Atrial Fibrillation
Neuropsychology
Eligibility:
All Genders
68-82 years
Phase:
PHASE4
Brief Summary
In elderly patients with atrial fibrillation (AF) the presence of silent brain infarcts and neurocognitive deficit is high despite adequate treatment with oral anticoagulation. Atherosclerosis is cons...
Eligibility Criteria
Inclusion
- Elderly patients (\>68 and \<82 years) with atrial fibrillation and adequate oral anticoagulation therapy and cholesterol levels between 4,5 mmol/l and 7 mmol/l
Exclusion
- Indication for cholesterol lowering treatment according to Dutch CBO-cholesterol guidelines (2004)
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00449410
Start Date
May 1 2005
End Date
October 1 2006
Last Update
March 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gheorghe AM Pop
Nijmegen, Netherlands, 6500 HB